Cargando…

Hemoadsorption by CytoSorb in septic patients: a case series

BACKGROUND: Septic shock, defined as life-threatening organ dysfunction caused by a dysregulated host response to infection, is a highly lethal condition that causes substantial morbidity and mortality among critically ill patients. One of the hallmarks of sepsis is the excessive release of cytokine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kogelmann, Klaus, Jarczak, Dominik, Scheller, Morten, Drüner, Matthias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5366999/ https://www.ncbi.nlm.nih.gov/pubmed/28343448 http://dx.doi.org/10.1186/s13054-017-1662-9

Ejemplares similares

First Evaluation of a New Dynamic Scoring System Intended to Support Prescription of Adjuvant CytoSorb Hemoadsorption Therapy in Patients with Septic Shock
por: Kogelmann, Klaus, et al.
Publicado: (2021)

Reply to Supady et al. On the Use of Hemadsorption with CytoSorb in Patients with Septic Shock. Comment on “Kogelmann et al. First Evaluation of a New Dynamic Scoring System Intended to Support Prescription of Adjuvant CytoSorb Hemoadsorption Therapy in Patients with Septic Shock. J. Clin. Med. 2021, 10, 2939”
por: Kogelmann, Klaus, et al.
Publicado: (2022)

Experience with hemoadsorption (CytoSorb(®)) in the management of septic shock patients
por: Mehta, Yatin, et al.
Publicado: (2020)

Hemoadsorption in the critically ill—Final results of the International CytoSorb Registry
por: Hawchar, Fatime, et al.
Publicado: (2022)

Pharmacokinetics of anti-infective agents during CytoSorb hemoadsorption
por: Schneider, Antoine G., et al.
Publicado: (2021)

Hemoadsorption with CytoSorb(®) and the early course of linezolid plasma concentration during septic shock
por: Köhler, Thomas, et al.
Publicado: (2021)

Hemoadsorption in ‘Liver Indication’—Analysis of 109 Patients’ Data from the CytoSorb International Registry
por: Ocskay, Klementina, et al.
Publicado: (2021)

Cytokine hemoadsorption with CytoSorb® in patients with sepsis: a systematic review and meta-analysis
por: Saldaña-Gastulo, Jiovany Jhan Carlos, et al.
Publicado: (2023)

Hemoadsorption Treatment with CytoSorb® in Probable Hemophagocytic Lymphohistiocytosis: A Role as Adjunctive Therapy?
por: Ceruti, Samuele, et al.
Publicado: (2021)

CytoSorb-friend or foe!!
por: Pattnaik, Saroj Kumar, et al.
Publicado: (2015)

Sublingual Microcirculatory Evaluation of Extracorporeal Hemoadsorption with CytoSorb® in Abdominal Sepsis: A Case Report
por: Duran, Servet, et al.
Publicado: (2022)

Hemoadsorption Using CytoSorb(®) in Patients with Infective Endocarditis: A German-Based Budget Impact Analysis
por: Rao, Cristina, et al.
Publicado: (2023)

CytoSorb® Hemoadsorption as a Promising Tool to Handle COVID-19-Induced Cytokine Storm
por: Acevedo, Alice-Christin, et al.
Publicado: (2021)

Does adjunctive hemoadsorption with CytoSorb affect survival of COVID-19 patients on ECMO? Authors' response
por: Supady, Alexander, et al.
Publicado: (2021)

Use of CytoSorb® hemoadsorption column during prolonged cardiopulmonary bypass in complex cardiac surgery patient
por: Alarie, Marianne, et al.
Publicado: (2022)

Hemoadsorption of cytokines by CytoSorb filter: a simulation study without human factor—pilot is the difference
por: Nadeem, Rashid, et al.
Publicado: (2020)

Therapeutic Modulation of the Host Defense by Hemoadsorption with CytoSorb(®)—Basics, Indications and Perspectives—A Scoping Review
por: Köhler, Thomas, et al.
Publicado: (2021)

Cytokine hemoadsorption with CytoSorb(®) in post-cardiac arrest syndrome, a pilot randomized controlled trial
por: Monard, Céline, et al.
Publicado: (2023)

Does adjunctive hemoadsorption with CytoSorb affect survival of COVID-19 patients on ECMO? A critical statement
por: Köhler, Thomas, et al.
Publicado: (2021)

Impact of CytoSorb and CKRT on hemodynamics in pediatric patients with septic shock: the PedCyto study
por: Bottari, Gabriella, et al.
Publicado: (2023)

Use of CytoSorb in Traumatic Amputation of the Forearm and Severe Septic Shock
por: Steltzer, Heinz, et al.
Publicado: (2017)

Hemoadsorption with CytoSorb in Septic Shock Reduces Catecholamine Requirements and In-Hospital Mortality: A Single-Center Retrospective ‘Genetic’ Matched Analysis
por: Rugg, Christopher, et al.
Publicado: (2020)

Reply: Does adjunctive hemoadsorption with CytoSorb® affect survival of COVID-19 patients on ECMO? A critical statement
por: Putzu, Alessandro, et al.
Publicado: (2021)

On the Use of Hemadsorption with CytoSorb in Patients with Septic Shock. Comment on Kogelmann et al. First Evaluation of a New Dynamic Scoring System Intended to Support Prescription of Adjuvant CytoSorb Hemoadsorption Therapy in Patients with Septic Shock. J. Clin. Med. 2021, 10, 2939
por: Supady, Alexander, et al.
Publicado: (2022)

Rapid reduction of substantially increased myoglobin and creatine kinase levels using a hemoadsorption device (CytoSorb(®))—A case report
por: Moresco, Erich, et al.
Publicado: (2022)

Use of CytoSorb© Hemoadsorption in Patients on Veno-Venous ECMO Support for Severe Acute Respiratory Distress Syndrome: A Systematic Review
por: Akil, Ali, et al.
Publicado: (2022)

Impact of CytoSorb® on interleukin-6 in cardiac surgery
por: Geisler, Daniela, et al.
Publicado: (2023)

Extracorporeal hemoadsorption in critically ill COVID-19 patients on VV ECMO: the CytoSorb therapy in COVID-19 (CTC) registry
por: Hayanga, J. W. Awori, et al.
Publicado: (2023)

Prevention of vasoplegia with CytoSorb in heart failure patients undergoing cardiac surgery (CytoSorb-HF trial): protocol for a randomised controlled trial
por: Papazisi, Olga, et al.
Publicado: (2022)

Pancreatitis cytosorbents (CytoSorb) inflammatory cytokine removal: A Prospective Study (PACIFIC)
por: Huber, Wolfgang, et al.
Publicado: (2019)

Cardiogenic Shock in a Hemodialyzed Patient on Flecainide: Treatment with Intravenous Fat Emulsion, Extracorporeal Cardiac Life Support, and CytoSorb® Hemoadsorption
por: De Schryver, Nicolas, et al.
Publicado: (2019)

Mortality and adverse events of hemoadsorption with CytoSorb® in critically ill patients: A systematic review and meta‐analysis of randomized controlled trials
por: Heymann, Marc, et al.
Publicado: (2022)

Comment on: Extracorporeal hemoadsorption in critically ill COVID‑19 patients on VV ECMO: the CytoSorb therapy in COVID‑19 (CTC) registry
por: Supady, A., et al.
Publicado: (2023)

CytoSorb removes MDMA in vitro, but is it an effective therapy in vivo?
por: Honore, Patrick M., et al.
Publicado: (2020)

Efficacy of CytoSorb®: a systematic review and meta-analysis
por: Becker, Sören, et al.
Publicado: (2023)

Hemadsorption with Adult CytoSorb® in a Low Weight Pediatric Case
por: Cirstoveanu, Catalin Gabriel, et al.
Publicado: (2017)

No clinically relevant removal of meropenem by cytokine adsorber CytoSorb(®) in critically ill patients with sepsis or septic shock
por: Liebchen, Uwe, et al.
Publicado: (2021)

Use of CytoSorb therapy to treat critically ill coronavirus disease 2019 patients: a case series
por: Mehta, Yatin, et al.
Publicado: (2021)

Hemoadsorption with CytoSorb shows a decreased observed versus expected 28-day all-cause mortality in ICU patients with septic shock: a propensity-score-weighted retrospective study
por: Brouwer, Willem Pieter, et al.
Publicado: (2019)

Impact of Continuous Kidney Replacement Therapy and Hemoadsorption with CytoSorb on Antimicrobial Drug Removal in Critically Ill Children with Septic Shock: A Single-Center Prospective Study on a Pediatric Cohort
por: Bottari, Gabriella, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_22jsias5drdfqb32o5k6vd52f5